Section Arrow
Quote
CKPT.NASDAQ
- Checkpoint Therapeutics
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Last
 4.03
-0.03 (-0.74%)
Day High 
4.06 
Prev. Close
4.06 
1-M High
4.08 
Volume 
1.15M 
Bid
4.03
Ask
4.04
Day Low
4.03 
Open
4.05 
1-M Low
2.365 
Market Cap 
224.36M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.03 
20-SMA 3.52 
50-SMA 3.29 
52-W High 4.5 
52-W Low 1.38 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.83/0.92
Enterprise Value
224.36M
Balance Sheet
Book Value Per Share
-0.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
103.00K
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed：2025/03/28 08:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patientswith solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.